{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:39:19Z","timestamp":1775104759378,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82772526"],"award-info":[{"award-number":["82772526"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374536"],"award-info":[{"award-number":["82374536"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["No SZZYSM202311011"],"award-info":[{"award-number":["No SZZYSM202311011"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20230807120508018"],"award-info":[{"award-number":["JCYJ20230807120508018"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04760-1","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:09:04Z","timestamp":1761815344000},"page":"5193-5203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Icariside II sensitizes osteosarcoma to doxorubicin through the lincROR\/Wnt\/\u03b2-catenin signaling regulatory axis"],"prefix":"10.1007","volume":"399","author":[{"given":"Shu-ting","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-xin","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-xiang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"1","key":"4760_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An Y, Duan H (2022) The role of m6A RNA methylation in cancer metabolism. Mol Cancer 21(1):14","journal-title":"Mol Cancer"},{"issue":"1","key":"4760_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23805","volume":"10","author":"W Chen","year":"2024","unstructured":"Chen W, Liu G, Zhang Y (2024) Production of rhamnosyl icariside II by snailase hydrolysis of Epimedium wushanense extracts. Heliyon 10(1):e23805","journal-title":"Heliyon"},{"key":"4760_CR3","doi-asserted-by":"publisher","first-page":"155346","DOI":"10.1016\/j.prp.2024.155346","volume":"259","author":"S Fuloria","year":"2024","unstructured":"Fuloria S, Yadav G, Menon SV, Ali H, Pant K, Kaur M, Deorari M, Sekar M, Narain K, Kumar S, Fuloria NK (2024) Targeting the Wnt\/beta-catenin cascade in osteosarcoma: the potential of ncRNAs as biomarkers and therapeutics. Pathol Res Pract 259:155346","journal-title":"Pathol Res Pract"},{"key":"4760_CR4","doi-asserted-by":"publisher","first-page":"1415722","DOI":"10.3389\/fendo.2024.1415722","volume":"15","author":"S Hu","year":"2024","unstructured":"Hu S, Han X, Liu G, Wang S (2024) LncRNAs as potential prognosis\/diagnosis markers and factors driving drug resistance of osteosarcoma, a review. Front Endocrinol (Lausanne) 15:1415722","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"4760_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1158\/1541-7786.MCR-22-0458","volume":"21","author":"X Jiang","year":"2023","unstructured":"Jiang X, Xu Y, Liu R, Guo S (2023) Exosomal lincROR promotes docetaxel resistance in prostate cancer through a beta-catenin\/HIF1alpha positive feedback loop. Mol Cancer Res 21(5):472\u2013482","journal-title":"Mol Cancer Res"},{"issue":"1","key":"4760_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejphar.2010.11.032","volume":"654","author":"SH Kim","year":"2011","unstructured":"Kim SH, Ahn KS, Jeong SJ, Kwon TR, Jung JH, Yun SM, Han I, Lee SG, Kim DK, Kang M, Chen CY, Lee JW, Kim SH (2011) Janus activated kinase 2\/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells. Eur J Pharmacol 654(1):10\u201316","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4760_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2023.2276384","volume":"18","author":"HW Kim","year":"2023","unstructured":"Kim HW, Baek M, Jung S, Jang S, Lee H, Yang SH, Kwak BS, Kim SJ (2023) ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer. Epigenetics 18(1):2276384","journal-title":"Epigenetics"},{"issue":"5","key":"4760_CR8","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.1002\/jcp.27435","volume":"234","author":"Z Kun-Peng","year":"2019","unstructured":"Kun-Peng Z, Chun-Lin Z, Xiao-Long M, Lei Z (2019) Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1\/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells. J Cell Physiol 234(5):6927\u20136939","journal-title":"J Cell Physiol"},{"issue":"8","key":"4760_CR9","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1007\/s12094-023-03119-3","volume":"25","author":"J Li","year":"2023","unstructured":"Li J, Jiang W, Shan W, Luo A, Qu G, Zhang J, Luo X, Xia J (2023) The synergistic anticancer effect of CBD and DOX in osteosarcoma. Clin Transl Oncol 25(8):2408\u20132418","journal-title":"Clin Transl Oncol"},{"key":"4760_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.632206","volume":"12","author":"R Li","year":"2021","unstructured":"Li R, Ruan Q, Zheng J, Zhang B, Yang H (2021) LINC01116 promotes doxorubicin resistance in osteosarcoma by epigenetically silencing miR-424-5p and inducing epithelial-mesenchymal transition. Front Pharmacol 12:632206","journal-title":"Front Pharmacol"},{"issue":"1","key":"4760_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jpp\/rgac067","volume":"75","author":"SY Li","year":"2023","unstructured":"Li SY, Shi CJ, Fu WM, Zhang JF (2023) Berberine inhibits tumour growth in vivo and in vitro through suppressing the lincROR-Wnt\/beta-catenin regulatory axis in colorectal cancer. J Pharm Pharmacol 75(1):129\u2013138","journal-title":"J Pharm Pharmacol"},{"key":"4760_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2021.02.007","volume":"504","author":"Z Lin","year":"2021","unstructured":"Lin Z, Xie X, Lu S, Liu T (2021) Noncoding RNAs in osteosarcoma: implications for drug resistance. Cancer Lett 504:91\u2013103","journal-title":"Cancer Lett"},{"key":"4760_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184528","author":"M Louca","year":"2022","unstructured":"Louca M, Gkretsi V (2022) Lincrnas and snornas in breast cancer cell metastasis: the unknown players. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14184528","journal-title":"Cancers (Basel)"},{"key":"4760_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040683","author":"L Marchandet","year":"2021","unstructured":"Marchandet L, Lallier M, Charrier C, Baud\u2019Huin M, Ory B, Lamoureux F (2021) Mechanisms of resistance to conventional therapies for osteosarcoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13040683","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4760_CR15","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1097\/JS9.0000000000002195","volume":"111","author":"Y Pei","year":"2025","unstructured":"Pei Y, Li S (2025) Unraveling the impact of noncoding RNAs in osteosarcoma drug resistance: a review of mechanisms and therapeutic implications. Int J Surg 111(2):2112\u20132130","journal-title":"Int J Surg"},{"issue":"1","key":"4760_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ncrna9010012","volume":"9","author":"JA Pena-Flores","year":"2023","unstructured":"Pena-Flores JA, Enriquez-Espinoza D, Muela-Campos D, Alvarez-Ramirez A, Saenz A, Barraza-Gomez AA, Bravo K, Estrada-Macias ME, Gonzalez-Alvarado K (2023) Functional relevance of the long intergenic non-coding RNA regulator of reprogramming (Linc-ROR) in cancer proliferation, metastasis, and drug resistance. Non-Coding RNA 9(1):12","journal-title":"Non-Coding RNA"},{"issue":"2","key":"4760_CR17","first-page":"427","volume":"52","author":"AM Saadat","year":"2023","unstructured":"Saadat AM, Gholipour A, Bagheri MM, Oveisee M, Mowla SJ, Malakootian M (2023) Differential expression of lincRNA-ROR spliced transcript variants in breast cancer. Iran J Public Health 52(2):427\u2013435","journal-title":"Iran J Public Health"},{"issue":"10","key":"4760_CR18","doi-asserted-by":"publisher","first-page":"e1879578174","DOI":"10.1073\/pnas.2415389122","volume":"122","author":"T Saxena","year":"2025","unstructured":"Saxena T, Quan A, Chan E, Kozlova N, Matai L, Lee JD, Rupaimoole R, Beca F, Muranen T, Slack FJ (2025) EGFR-induced lncRNATRIDENT promotes drug resistance in non\u2013small cell lung cancer via phospho-TRIM28-mediated DNA damage repair. Proc Natl Acad Sci U S A 122(10):e1879578174","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4760_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105800","volume":"124","author":"C Shi","year":"2022","unstructured":"Shi C, Li S, Shen C, Pan F, Deng L, Fu W, Wang J, Zhang J (2022) Icariside II suppressed tumorigenesis by epigenetically regulating the circ\u03b2-catenin-Wnt\/\u03b2-catenin axis in colorectal cancer. Bioorg Chem 124:105800","journal-title":"Bioorg Chem"},{"issue":"4","key":"4760_CR20","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s10565-022-09777-3","volume":"39","author":"C Shi","year":"2023","unstructured":"Shi C, Lv M, Deng L, Zeng W, Fu W, Zhang J (2023) Linc-ROR drive adriamycin resistance by targeting AP-2\u03b1\/Wnt\/\u03b2-catenin axis in hepatocellular carcinoma. Cell Biol Toxicol 39(4):1735\u20131752","journal-title":"Cell Biol Toxicol"},{"key":"4760_CR21","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.drup.2022.100851","volume":"63","author":"D Singh","year":"2022","unstructured":"Singh D, Assaraf YG, Gacche RN (2022) Long non-coding RNA mediated drug resistance in breast cancer. Drug Resist Updat 63:100851","journal-title":"Drug Resist Updat"},{"issue":"10","key":"4760_CR22","doi-asserted-by":"publisher","first-page":"e11155","DOI":"10.1016\/j.heliyon.2022.e11155","volume":"8","author":"S Soghala","year":"2022","unstructured":"Soghala S, Harsiny K, Momeni P, Hatami M, Kholghi OV, Hussen BM, Taheri M, Ghafouri-Fard S (2022) Down-regulation of LINC-ROR, HOXA-AS2 and MEG3 in gastric cancer. Heliyon 8(10):e11155","journal-title":"Heliyon"},{"key":"4760_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175781","volume":"951","author":"A Taheriazam","year":"2023","unstructured":"Taheriazam A, Bayanzadeh SD, Heydari FM, Mojtabavi S, Zandieh MA, Gholami S, Heydargoy MH, Jamali HM, Kangarloo Z, Behroozaghdam M, Khorrami R, Sheikh BGM, Salimimoghadam S, Rashidi M, Hushmandi K, Entezari M, Hashemi M (2023) Non-coding RNA-based therapeutics in cancer therapy: an emphasis on Wnt\/beta-catenin control. Eur J Pharmacol 951:175781","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"4760_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317705745","volume":"39","author":"Y Tang","year":"2017","unstructured":"Tang Y, Xie M, Jiang N, Huang F, Zhang X, Li R, Lu J, Liao S, Liu Y (2017) Icarisid II inhibits the proliferation of human osteosarcoma cells by inducing apoptosis and cell cycle arrest. Tumour Biol 39(6):1393383919","journal-title":"Tumour Biol"},{"issue":"3","key":"4760_CR25","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1080\/21655979.2022.2045090","volume":"13","author":"J Tang","year":"2022","unstructured":"Tang J, Zhu Z, Dong S, Wang Y, Wang J, Chen H, Duan G (2022) Long non-coding RNA long intergenic non-coding 00641 mediates cell progression with stimulating cisplatin-resistance in osteosarcoma cells via microRNA-320d\/myeloid cell leukemia-1 axis. Bioengineered 13(3):7238\u20137252","journal-title":"Bioengineered"},{"issue":"9","key":"4760_CR26","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1016\/j.fct.2012.06.027","volume":"50","author":"J Wu","year":"2012","unstructured":"Wu J, Guan M, Wong PF, Yu H, Dong J, Xu J (2012) Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway. Food Chem Toxicol 50(9):3019\u20133024","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"4760_CR27","doi-asserted-by":"publisher","first-page":"e70048","DOI":"10.1002\/ddr.70048","volume":"86","author":"Q Wu","year":"2025","unstructured":"Wu Q, Zhu C, Zhao T, Liu T, Da M (2025) Downregulation of LncRNA CCAT1 enhances chemosensitivity in cisplatin-resistant gastric cancer cells. Drug Dev Res 86(1):e70048","journal-title":"Drug Dev Res"},{"key":"4760_CR28","doi-asserted-by":"publisher","first-page":"663776","DOI":"10.3389\/fphar.2021.663776","volume":"12","author":"F Xu","year":"2021","unstructured":"Xu F, Wu Q, Li L, Gong J, Huo R, Cui W (2021) Icariside II: anticancer potential and molecular targets in solid cancers. Front Pharmacol 12:663776","journal-title":"Front Pharmacol"},{"issue":"6","key":"4760_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/1120009X.2022.2157618","volume":"35","author":"J Xu","year":"2023","unstructured":"Xu J, Xu Y, Ye G, Qiu J (2023) Lncrna-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis. J Chemother 35(6):527\u2013538","journal-title":"J Chemother"},{"issue":"4","key":"4760_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/EBC20200032","volume":"65","author":"H Yan","year":"2021","unstructured":"Yan H, Bu P (2021) Non-coding RNA in cancer. Essays Biochem 65(4):625\u2013639","journal-title":"Essays Biochem"},{"key":"4760_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2018.07.031","volume":"356","author":"Q Yang","year":"2018","unstructured":"Yang Q, Chen W, Xu Y, Lv X, Zhang M, Jiang H (2018) Polyphyllin I modulates MALAT1\/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. Toxicol Appl Pharmacol 356:1\u20137","journal-title":"Toxicol Appl Pharmacol"},{"key":"4760_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2018.12.026","volume":"846","author":"J Yang","year":"2019","unstructured":"Yang J, Lan J, Du H, Zhang X, Li A, Zhang X, Liu Y, Zhang J, Zhang C, Ding Y, Zhang T (2019) Icariside II induces cell cycle arrest and differentiation via TLR8\/MyD88\/p38 pathway in acute myeloid leukemia cells. Eur J Pharmacol 846:12\u201322","journal-title":"Eur J Pharmacol"},{"issue":"14","key":"4760_CR33","doi-asserted-by":"publisher","first-page":"14406","DOI":"10.18632\/aging.103484","volume":"12","author":"J Ye","year":"2020","unstructured":"Ye J, Sun D, Yu Y, Yu J (2020) Osthole resensitizes CD133(+) hepatocellular carcinoma cells to cisplatin treatment via PTEN\/AKT pathway. Aging (Albany NY) 12(14):14406\u201314417","journal-title":"Aging (Albany NY)"},{"key":"4760_CR34","doi-asserted-by":"publisher","first-page":"7347298","DOI":"10.1155\/2020\/7347298","volume":"2020","author":"X Yu","year":"2020","unstructured":"Yu X, Ding H, Shi Y, Yang L, Zhou J, Yan Z, Xiao B (2020) Downregulated expression of linc-ROR in gastric cancer and its potential diagnostic and prognosis value. Dis Markers 2020:7347298","journal-title":"Dis Markers"},{"key":"4760_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114129","volume":"201","author":"N Zhang","year":"2021","unstructured":"Zhang N, Gao M, Wang Z, Zhang J, Cui W, Li J, Zhu X, Zhang H, Yang DH, Xu X (2021) Curcumin reverses doxorubicin resistance in colon cancer cells at the metabolic level. J Pharm Biomed Anal 201:114129","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"4760_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12938-021-00860-0","volume":"20","author":"X Zhao","year":"2021","unstructured":"Zhao X, Wu Q, Gong X, Liu J, Ma Y (2021) Osteosarcoma: a review of current and future therapeutic approaches. Biomed Eng Online 20(1):24","journal-title":"Biomed Eng Online"},{"key":"4760_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.omtn.2019.04.008","volume":"16","author":"Y Zhi","year":"2019","unstructured":"Zhi Y, Abudoureyimu M, Zhou H, Wang T, Feng B, Wang R, Chu X (2019) FOXM1-mediated LINC-ROR regulates the proliferation and sensitivity to sorafenib in hepatocellular carcinoma. Mol Ther Nucleic Acids 16:576\u2013588","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"4760_CR38","doi-asserted-by":"publisher","first-page":"17990","DOI":"10.1021\/acsami.4c21331","volume":"17","author":"J Zhou","year":"2025","unstructured":"Zhou J, Lin G, Fu X, Qiu S, Zhang Y, Chen X, Liu Y, Wan X, Li Z, Li Y, Mo F, Shen H, Sun Q, Sun J, Liu J (2025) ZIF-8-modified multifunctional hydrogel loading siRNA and DOX for postoperative therapy of maxillofacial osteosarcoma and bone repair. ACS Appl Mater Interfaces 17(12):17990\u201318002","journal-title":"ACS Appl Mater Interfaces"},{"key":"4760_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cca.2020.11.015","volume":"512","author":"Y Zou","year":"2021","unstructured":"Zou Y, Chen B (2021) Long non-coding RNA HCP5 in cancer. Clin Chim Acta 512:33\u201339","journal-title":"Clin Chim Acta"},{"issue":"6","key":"4760_CR40","doi-asserted-by":"publisher","first-page":"e22480","DOI":"10.1002\/jbt.22480","volume":"34","author":"J Zou","year":"2020","unstructured":"Zou J, Su H, Zou C, Liang X, Fei Z (2020) Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling. J Biochem Mol Toxicol 34(6):e22480","journal-title":"J Biochem Mol Toxicol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04760-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04760-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04760-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:13:01Z","timestamp":1775099581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04760-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4760"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04760-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}